Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg

被引：6
|
作者：
Cheung, Ka-Chun [1 ]
Wong, Lap-Gate [2 ]
Yeung, Yiu-Ming [1 ]
机构：
[1] Tuen Mun Hosp, Dept Med & Geriatr, Haematol Team, Hong Kong, Peoples R China
[2] Tuen Mun Hosp, Dept Pathol, Hong Kong, Peoples R China
来源：
LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 03期
关键词：
D O I：
10.1080/10428190701882161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：596 / 597
页数：2
相关论文
共 50 条
  • [41] Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
    Boucher, Justin C.
    Shrestha, Bishwas
    Vishwasrao, Paresh
    Leick, Mark
    Cervantes, Estelle V.
    Ghafoor, Tayyebb
    Reid, Kayla
    Spitler, Kristen
    Yu, Bin
    Betts, Brian C.
    Guevara-Patino, Jose A.
    Maus, Marcela V.
    Davila, Marco L.
    MOLECULAR THERAPY ONCOLYTICS, 2023, 31
  • [42] Construction and characterization of novel CD33/CD3 tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia (AML).
    Reusch, Uwe
    Harrington, Kimberly H.
    Gudgeon, Chelsea J.
    Fucek, Ivica
    Ellwanger, Kristina
    Weichel, Michael
    Knackmuss, Stefan
    Zhukovsky, Eugene
    Fox, Judith A.
    Guenot, Jeanmarie
    Walter, Roland B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Chimeric Antigen Receptor-Modified T Cells for the Treatment of Acute Myeloid Leukemia Expressing CD33
    Song, Degang
    Swartz, Michael H.
    Biesecker, Steve G.
    Borda, Fernando
    Shah, Rutul R.
    Emtage, Peter
    Wierda, William G.
    Cooper, Laurence J. N.
    Chan, Tim
    BLOOD, 2016, 128 (22)
  • [44] Biting Leukemia: CD33/CD3 Bispecific Antibody Constructs for the Treatment of AML
    Subklewe, Marion
    ANNALS OF HEMATOLOGY, 2017, 96 : S46 - S46
  • [45] Diagnostic Value of CD33 by Immunohistochemistry in Leukemia Cutis
    Ma, L.
    Kim, D. S. L.
    Cutlan, J.
    Ross, C.
    Lim, M.
    Fullen, D.
    MODERN PATHOLOGY, 2009, 22 : 106A - 106A
  • [46] Diagnostic Value of CD33 by Immunohistochemistry in Leukemia Cutis
    Ma, L.
    Kim, D. S. L.
    Cutlan, J.
    Ross, C.
    Lim, M.
    Fullen, D.
    LABORATORY INVESTIGATION, 2009, 89 : 106A - 106A
  • [47] CD33 is variably expressed on leukemic stem cells in Acute Myelogenous Leukemia.
    Becker, MW
    Qian, DL
    BLOOD, 2001, 98 (11) : 587A - 587A
  • [48] Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
    Laszlo, George S.
    Harrington, Kimberly H.
    Gudgeon, Chelsea J.
    Beddoe, Mary E.
    Fitzgibbon, Matthew P.
    Ries, Rhonda E.
    Lamba, Jatinder K.
    McIntosh, Martin W.
    Meshinchi, Soheil
    Walter, Roland B.
    ONCOTARGET, 2016, 7 (28) : 43281 - 43294
  • [49] CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives
    Sperr, WR
    Florian, S
    Hauswirth, AW
    Valent, P
    LEUKEMIA & LYMPHOMA, 2005, 46 (08) : 1115 - 1120
  • [50] Newly diagnosed acute myeloid Leukemia Mylotarg® (Gemtuzumab Ozogamicin) is the first CD33 Antibody-Drug Conjugate approved for combined First-Line Therapy
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (10) : 659 - 659
12345